0.95
-6.91%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Lite Strategy
From its filings with the US Securities and Exchange Commission
Lite Strategy is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker LITS. The SEC classifies its business as finance services. In the fiscal year to 30 June 2025, it reported revenue of $0.
Lite Strategy, Inc. (Nasdaq: LITS) is a pharmaceutical company that has historically developed novel and differentiated cancer therapies. During fiscal year 2026, we commenced pre-clinical development programs in nononcologic disease indications. We also hold Litecoin (LTC) tokens as a primary reserve asset as part of our broader institutional treasury initiative. We initially built our pipeline by acquiring promising cancer agents and creating value in programs through clinical development, strategic partnerships, and out-licensing or commercialization, as appropriate. Our approach to pre-clinical drug development is to evaluate our drug candidates either as stand-alone or in combination with standard-of-care therapies to overcome known resistance mechanisms and address medical needs to provide improved patient benefit. Our drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, zandelisib, an oral, once-daily, selective PI3Kδ inhibitor and, prior to its sale in October 2024 to Aardvark Therapeutics, Inc., ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway in the mitochondria.
Quoted from its 10-K, filed 28 Sept 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Dec 2003
- Employees
- 4
- Website
- meipharma.com ↗
- Head office
- 9920 PACIFIC HEIGHTS BLVD, SAN DIEGO, CA, 92121
- Incorporated in
- DE
- Classification
- Finance Services
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Frederick DriscollIndependent Chairman of the Board$117,200
- Mr. Justin FileActing Chief Executive Officer, Chief Financial Officer, Corporate Secretary$614,700
- Dr. Nicholas GloverIndependent Director$122,783
- Dr. Thomas ReynoldsIndependent Director$115,283
- Mr. Joshua RiezmanIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 38
- Environment
- 12
- Social
- 62
- Governance
- 40
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MEI Pharma employs 40 full-time staff members in San Diego.
- The company focuses on clinical development of cancer therapies.
- Pracinostat targets hematologic diseases like acute myeloid leukemia and MDS.
Weaknesses
- Lite Strategy Inc has only four employees according to the facts.
- The company went public on 18 December 2003 in the US.
- San Diego is the headquarters city for the firm.
Opportunities
- ME-344 targets mitochondrial components in rapidly proliferating cancer cells.
- ME-401 inhibits PI3K delta in hematologic cancer cell survival.
- Pracinostat has been tested in multiple Phase I clinical trials.
Threats
- ME-401 is an oral inhibitor of phosphatidylinositide 3-kinase delta.
- ME-344 is an isoflavone-based mitochondrial inhibitor for cancer treatment.
- Pracinostat is an orally available histone deacetylase inhibitor for AML.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.